Supernus Pharmaceuticals Files 8-K
Ticker: SUPN · Form: 8-K · Filed: Jun 16, 2025 · CIK: 1356576
| Field | Detail |
|---|---|
| Company | Supernus Pharmaceuticals, Inc. (SUPN) |
| Form Type | 8-K |
| Filed Date | Jun 16, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, filing
Related Tickers: SUPN
TL;DR
SUPN signed a material definitive agreement, filing an 8-K on June 16, 2025.
AI Summary
On June 13, 2025, Supernus Pharmaceuticals, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company also reported other events and filed financial statements and exhibits. The filing was made on June 16, 2025.
Why It Matters
This 8-K filing indicates Supernus Pharmaceuticals has entered into a significant agreement, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which often carries significant implications for a company's future, but the specific nature of the agreement is not detailed.
Key Players & Entities
- Supernus Pharmaceuticals, Inc. (company) — Registrant
- June 13, 2025 (date) — Date of earliest event reported
- June 16, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Rockville, MD (location) — Principal Executive Offices
FAQ
What is the nature of the material definitive agreement entered into by Supernus Pharmaceuticals?
The filing does not disclose the specific details of the material definitive agreement.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 13, 2025.
On what date was this 8-K filing submitted to the SEC?
The filing was submitted on June 16, 2025.
What is Supernus Pharmaceuticals' principal executive office address?
The principal executive offices are located at 9715 Key West Ave, Rockville, MD 20850.
What is Supernus Pharmaceuticals' standard industrial classification?
The standard industrial classification is Pharmaceutical Preparations [2834].
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 16, 2025 regarding SUPERNUS PHARMACEUTICALS, INC. (SUPN).